BMCM
CGTX icon

Bryn Mawr Capital Management’s Cognition Therapeutics CGTX Stock Holding History

Bryn Mawr Capital Management’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.1K Hold
29,050
– – ﹤0.01% 438
2025
Q4 		$39.2K Sell
29,050
-10,416
-26% -$16.9K ﹤0.01% 446
2025
Q3 		$53.3K Buy
39,466
+16,129
+69% +$22K ﹤0.01% 437
2025
Q2 		$7.23K Hold
23,337
– – ﹤0.01% 419
2025
Q1 		$9.82K Hold
23,337
– – ﹤0.01% 387
2024
Q4 		$16.4K Buy
+23,337
New +$11.5K ﹤0.01% 411

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Bryn Mawr Capital Management's CGTX Position: Q1 2026 in Review

Bryn Mawr Capital Management held its Cognition Therapeutics (CGTX) position steady in Q1 2026 at 29,050 shares worth $22.1K. The position accounts for ﹤0.01% of the portfolio, ranked #438.

Bryn Mawr Capital Management first reported a position in CGTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $53.3K in Q3 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Bryn Mawr Capital Management held 29,050 shares of Cognition Therapeutics worth $22.1K as of Q1 2026.
  • Bryn Mawr Capital Management left its Cognition Therapeutics share count unchanged in Q1 2026.
  • Cognition Therapeutics made up ﹤0.01% of Bryn Mawr Capital Management's portfolio in Q1 2026, its #438 holding.
  • Bryn Mawr Capital Management first reported a position in Cognition Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Bryn Mawr Capital Management's Cognition Therapeutics position peaked at $53.3K in Q3 2025.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Bryn Mawr Capital Management's 13F filing for Q1 2026, filed 4 May 2026.